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Impact of Escherichia coli K12 
and O18:K1 on human platelets: 
Differential effects on platelet 
activation, RNAs and proteins
A. V. Fejes1, M. G. Best2,3,4, W. A. van der Heijden5, A. Vancura2,4, H. Verschueren2,4,  
Q. de Mast5, T. Wurdinger2,4 & C. Mannhalter1
Blood platelets can interact with bacteria, possibly leading to platelet activation, cytokine and 
microparticle release and immune signalling. Besides, bacteria can also affect the platelet RNA 
content. We investigated the impact of non-pathogenic K12 and pathogenic O18:K1 Escherichia (E.) coli 
strains on platelet activation, RNA expression patterns, and selected proteins. Depending on bacteria 
concentration, contact of platelets with E. coli K12 lead to an increase of P-selectin (24–51.3%), CD63 
(15.9–24.3%), PAC-1 (3.8–14.9%) and bound fibrinogen (22.4–39%) on the surface. E. coli O18:K1 
did not affect these markers. Sequencing analysis of total RNA showed that E. coli K12 caused a 
significant concentration change of 103 spliced mRNAs, of which 74 decreased. For the RNAs of HMBS 
(logFC = +5.73), ATP2C1 (logFC = −3.13) and LRCH4 (logFC = −4.07) changes were detectable by 
thromboSeq and Tuxedo pipelines. By Western blot we observed the conversion of HMBS protein from 
a 47 kDA to 40 kDa product by E. coli K12, O18:K1 and by purified lipopolysaccharide. While ATP2C1 
protein was released from platelets, E. coli either reduced the secretion or broke down the released 
protein making it undetectable by antibodies. Our results demonstrate that different E. coli strains 
influence activation, RNA and protein levels differently which may affect platelet-bacteria crosstalk.
Blood platelets are anucleated cells, derived from megakaryocytes in the bone marrow. They are continuously 
shed into and cleared from the blood stream maintaining a high abundance with 150–400 × 109 cells per litre of 
whole blood.
Platelets have an important role in haemostasis and thrombosis. They are packed with organelles, granules, 
RNA and proteins, which they primarily receive from their precursor cells. They have the capability to sequester 
proteins and RNA while in circulation1,2. It has been shown that platelets have a rich repertoire of RNAs, includ-
ing ribosomal, circular and micro RNAs3–5, and ~9500 messenger RNAs6. Platelets contain a functional cellular 
machinery and have the capability to splice pre-mRNA into its mature form7. It has been shown that activation 
of splicing can be induced by lipopolysaccharide (LPS)8, thrombin9 or a septic environment10. Furthermore, can-
cer11,12 and cardiovascular diseases13 can influence the platelet RNA profile. Upon thrombin activation, trans-
lation of certain spliced RNAs to proteins has been reported14,15, which proved the presence of a translational 
machinery in platelets.
Besides haemostasis, platelets are important for humoral as well as cellular immune responses. They are able to 
interact with bacteria, which may result in their activation, aggregation, release of granules and platelet-leukocyte 
complex formation16–19. Recently it has been shown that platelets can act as cellular scavengers; they collect 
deposited bacteria and recruit phagocytes to boost the inflammatory reaction20. The interaction of platelets with 
Gram-positive bacteria, such as Staphylococcus aureus and Streptococcus sanguinis, has been extensively studied. 
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It has been shown that both strains are able to trigger platelet aggregation21,22, S. sanguinis can induce cytokine 
release from platelets23, whereas S. aureus enhances thrombocytopenia24. The crosstalk between platelets and 
Gram-negative bacteria is less well characterized, although it has been shown that Gram-negative Escherichia 
coli25,26, Helicobacter pylori27–30 and Klebsiella pneumoniae31–33 have an activating or - in some cases - aggregating 
effect on platelets. E. coli are commensal bacteria of the gastrointestinal tract in humans and rarely cause disease. 
However, clones with specific virulence attributes exist which are able to induce clinical syndromes such as enteric 
disease, urinary tract infections and sepsis34. Some E. coli strains interact with platelets via the LPS ligand TLR435, 
FcγRIIA or integrin complex αIIbβ336,37. Little is known about the molecular consequences of the interactions 
between platelets and E. coli, and how they influence RNA or protein expression patterns or release of platelet 
contents.
We investigated the effects of a non-pathogenic (K12) and a pathogenic (O18:K1) E. coli strain on human 
platelets. We found that contact with E. coli K12 increases the activation markers P-selectin and CD63 on the 
platelet surface as well as PAC-1 and fibrinogen binding, while the pathogenic E. coli O18:K1 did not affect these 
markers. By next generation RNA sequencing, we found that the two E. coli strains affected different spliced plate-
let RNAs (mRNAs). Using two bioinformatics pipelines for analysis of RNA fingerprints we identified significant 
effects of E. coli on the mRNAs HMBS, ATP2C1 and LRCH4. To see whether these three proteins were present 
in platelets and were influenced by the bacteria, we analysed HMBS, ATP2C1 and LRCH4 in platelet lysates and 
releasates by Western blot and ELISA.
Results
E. coli K12 affects platelet activation. The effect of non-pathogenic (K12) and pathogenic (O18:K1) E. 
coli strains on platelet activation was measured by flow cytometry analyses of P-selectin and CD63 expression 
(Fig. 1), as well as the fibrinogen binding capacity of platelets (Fig. 2).
We observed an increase of P-selectin (24–51.3%, n = 3, p < 0.05) on the platelet’s surface exposed to E. coli 
K12 for either zero or three hours incubation compared to platelets not incubated with bacteria (Fig. 1a,b). 
P-selectin expression correlated with the number of bacteria added. The effect by E. coli K12 was rapid and 
reached the levels achieved by platelet activators TRAP and ADP already few minutes after addition of the bacte-
ria (zero hours, 1:5 platelet to bacteria ratio).
Similarly, CD63 also increased on the surface of platelets incubated with E. coli K12 (15.9–24.3%, n = 3, 
p < 0.05) compared to platelets not exposed to bacteria. Apparently, this effect was independent of the bacteria 
concentration (Fig. 1c,d).
Furthermore, we observed that E. coli K12 rapidly induced fibrinogen binding to the platelet surface (22.4–
39%, n = 3, p < 0.05) compared to control platelets (Fig. 2c,d).
Exposure of platelets to E. coli O18:K1 for zero or three hours did not induce a measurable increase of either 
P-selectin or CD63 on the platelet surface (n = 3) (Fig. 1a–d), and only insignificantly affected fibrinogen (n = 3) 
(Fig. 2c,d).
The responses of platelets to LPS are still controversial in spite of many attempts for clarification38,39. We 
observed that LPS was only able to induce a minor increase of surface P-selectin after three hours incubation 
(non-significant).
Also low number of E. coli K12 and O18:K1 per platelet (i.e. 10:1 platelet to bacteria ratio) did not increase 
platelet surface P-selectin or CD63 on co-incubated platelets versus control conditions (data not shown).
E. coli K12 induces activation of the integrin αIIbβ3 receptor. It is essential for platelet aggregation 
that integrin αIIb and integrin β3 form an active complex (integrin αIIbβIII) to which fibrinogen can bind. The 
complex formation is detected via binding a PAC-1 antibody, what we evaluated on platelets incubated without 
or with E. coli bacteria.
We observed that platelets exposed to E. coli K12 showed PAC-1 positivity already after few minutes (zero 
hours) of contact between platelets and E. coli K12 what corresponded to the number of bacteria added (3.8–
8.6%, n = 3, non-significant) (Fig. 2a). The antibody binding was increased after three hours incubation in sam-
ples containing a 5-fold or 10-fold bacteria excess over platelets (8.4–14.9%, n = 3, p < 0.05) (Fig. 2b).
E. coli O18:K1 did not trigger the binding of PAC-1 antibody (n = 3) (Fig. 2a,b).
Importantly, both bacteria strains were alive, but did not show measurable growth after three hours incubation 
in SSP + buffer at room temperature (sub-optimal conditions for bacteria growth) compared to zero hours. The 
presence of washed platelets did not significantly affect the number of E. coli K12 or O18:K1 colonies (data not 
shown).
E. coli K12 differentially alters platelet mRNAs. It has been shown that LPS and a septic environment 
may affect platelet RNA splicing8,10. We measured the influence of external platelet activation by E. coli strains on 
platelet mRNA repertoire by high-throughput mRNA-sequencing.
We incubated platelets isolated from healthy individuals (n = 4) with both E. coli strains in 1:1 platelet to bac-
teria ratio. Platelets of the same healthy individuals incubated without bacteria served as controls. Total RNA was 
isolated and subjected to RNA-sequencing. We included a poly-A-tailed oligo-dT amplification protocol to min-
imize the contribution of bacterial RNA to the platelet RNA profiles. We used thromboSeq pipeline11,12 to ana-
lyse our data. First, an average 9.1 × 106 reads in total per sample (n = 12, (SD) = 1.8 × 106) was observed, from 
which approximately 6.5 × 106 (n = 12, (SD) = 1.6 × 106) mapped to the human reference genome. We allowed 
for maximum ten mismatches per 100 base pairs RNA-sequencing reads between our reads and the human 
reference genome. Of these, 1.2 × 106 corresponded to intron-spanning domains (n = 12, (SD) = 2.6 × 105) 
(Supplementary Table S1). We specifically investigated intron-spanning RNA reads to uncover the potentially 
spliced RNA repertoire. We filtered for low abundant RNAs (logCPM >3) and removed those from the dataset. 
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The RNA-sequencing profiles of platelets correlated to previously published platelet RNA-sequencing datasets 
(Supplementary Fig. S2)3,6,40.
After E. coli K12 exposure 3072 platelet mRNAs were identified with high abundance, whereas 3095 mRNAs 
were detected after E. coli O18:K1 exposure of platelets. Thus, incubation of platelets from four healthy donors 
with E. coli K12 (Fig. 3) or E. coli O18:K1 (Supplementary Fig. S3) (1:1 platelet to bacteria ratio, three hours incu-
bation) influenced platelet RNAs.
By ANOVA likelihood-ratio test for detection of differentially expressed RNAs, we could show that exposure 
of platelets to E. coli K12 affected the concentration of 103 spliced RNAs statistically significantly (n = 4 individ-
uals’ platelets incubated without E. coli, n = 4 individuals’ platelets incubated with E. coli K12, p < 0.05). The level 
of 29 RNAs was increased (+3.77 average logarithm 2 fold change (logFC)), and of 74 RNAs decreased (−4.98 
average logFC) (Fig. 3b). The changes allowed a clear differentiation between pre- and post- E. coli K12 contact 
(p < 0.001 by Fischer’s exact test) (Fig. 3a).
Interestingly, only 21 RNAs which were affected overlapped between E. coli K12 and O18:K1 profiles 
(Supplementary Fig. S3d).
Gene ontology (GO) functional annotation analysis using Database for Annotation, Visualization and 
Integrated Discovery (DAVID) was performed for all RNAs with significantly changed concentration (p < 0.05) 
(Fig. 3c, Supplementary Tables S3, S4). We found that incubation of platelets with E. coli K12 caused an enrich-
ment of RNAs with the following functional characteristics: involved in splicing (Cluster 4, 15 RNAs), cell-cell 
adhesion (Cluster 5 with 7 RNAs), related to Golgi apparatus (Cluster 2, 11 members) and ubiquitin related pro-
cesses (Cluster 1 with 13 and Cluster 3 with 5 RNAs) (cluster enrichment score >1).
Figure 1. P-selectin and CD63 expression on platelets after co-incubation with bacteria or platelet activators. 
P-selectin (a,b) or CD63 (c,d) were measured on the platelet surface by flow cytometry after gating for the 
presence of CD41. Platelets incubated without bacteria (PLT) and E. coli K12 or O18:K1 co-incubated platelets 
(platelet-bacteria ratios 1:1, 1:5, 1:10) were analysed at zero hours (a,c) and after three hours (b,d) incubation. 
The activating effect of bacteria was compared to platelet activation by TRAP, ADP or LPS after 15 minutes 
or three hours incubation time. The data represents percentages (mean ± standard error of the mean) from 
3–6 independent experiments. Activation was compared to PLT controls, significance levels are: *p < 0.05, 
**p < 0.01, and ***p < 0.001. TRAP, thrombin receptor activating peptide 6; ADP, adenosine diphosphate; LPS, 
lipopolysaccharide.
www.nature.com/scientificreports/
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When we tested the effects of E. coli K12 on platelet RNA concentrations with the Tuxedo RNA-sequencing 
processing41–43 pipeline, we observed significant concentration changes of RNAs, particularly hydroxymethylb-
ilane synthase (HMBS), encoding for the protein porphobilinogen deaminase, an enzyme contributing to heme 
biosynthesis; ATPase secretory pathway Ca2+ transporting 1 (ATP2C1), a protein involved in calcium ion trans-
port in a magnesium-dependent manner; and leucine rich repeats and calponin homology domain containing 
4 (LRCH4), translated to a protein with leucine-rich repeats (LRR) involved in ligand binding in both pipelines 
(Fig. 3d).
We could validate the presence of HMBS, ATP2C1 and LRCH4 in platelets by RT- PCR analysis. Even though 
RT-PCR is a semi-quantitative method, we could confirm the same trend of changes of the tested platelet RNAs 
induced by E. coli K12 that we observed by RNA-seqencing. Using human-sequence specific RT-PCR primers, 
we made sure that the changes are independent of potential HMBS, ATP2C1, and LRCH4 production by bacteria 
(data not shown).
HMBS RNA44 as well as ATP2C1 RNA and protein45,46 have been reported to be present in platelets, but their 
functions remain largely unclear. The presence of LRCH4 had not been described in platelets yet. Until now, the 
effect of E. coli on these RNAs in platelets has not been investigated. Our data indicates that exposure of platelets 
to E. coli K12 results in an increase of HMBS (logFC = +5.73), and a decrease of ATP2C1 (logFC = −3.13) and 
LRCH4 (logFC = −4.07) RNA.
Effect of E. coli on HMBS, ATP2C1 and LRCH4 proteins in platelets. Alterations of platelet mRNA 
may influence the platelet protein content as well.
By Western blot analysis we could demonstrate the presence of HMBS, ATP2C1 and LRCH4 proteins in plate-
lets before and after E. coli K12 exposure (in 1:1, 1:5 and 1:10 platelet to bacteria ratios) (Fig. 4a, Supplementary 
Fig. S4).
Figure 2. PAC-1 antibody and fibrinogen binding on platelet surface after co-incubation with E. coli K12 or 
O18:K1. PAC-1 antibody (a,b) and fibrinogen (c,d) binding were measured on the platelet surface by flow 
cytometry after gating for the presence of CD61. Platelets incubated without bacteria (PLT) and E. coli K12 
or O18:K1 co-incubated platelets (platelet-bacteria ratios 1:1, 1:5, 1:10) were analysed at zero hours (a,c) and 
after three hours (b,d). TRAP treated platelets served as a positive control after 15 minutes or three hours 
incubation time. The data represents percentages (mean ± standard error of the mean) from three independent 
experiments. Activation was compared to PLT controls, significance levels are: *p < 0.05, **p < 0.01, and 
***p < 0.001. TRAP, thrombin receptor activating peptide 6.
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We detected no visible concentration difference or molecular weight change of ATP2C1 and LRCH4 in plate-
lets after E. coli K12 exposure. In contrast, when present in 5-fold or 10-fold excess over platelets, E. coli K12 
converted HMBS from a 47 kDa form to a 40 kDa molecular weight protein.
We also evaluated the effect of E. coli O18:K1 (Fig. 4a, Supplementary Fig. S4) as well as of the platelet agonists 
TRAP, ADP and LPS on the HMBS, LRCH4 and ATP2C1 proteins (Fig. 5, Supplementary Fig. S5). We saw that 
E. coli O18:K1 and LPS converted HMBS to the 40 kDa form. Interestingly, LPS had little influence on platelet 
activation of washed platelets (Fig. 1). Neither E. coli O18:K1, nor the three platelet activators had any effect on 
the protein levels or molecular weight of ATP2C1 or LRCH4.
Figure 3. Changes of mRNAs in platelets after exposure to E. coli K12. Analysis with thromboSeq pipeline. (a) 
Heatmap of platelet mRNA profiles of control (grey) and E. coli K12 co-incubated platelets (green) after three 
hours incubation in 1:1 platelet-bacteria ratio. (b) Volcano plot of mRNAs of control versus E. coli K12 (1:1) 
exposed platelets. RNAs of which the concentrations changed significantly after E. coli K12 co-incubation are 
labelled in red (p < 0.05). (c) Gene ontology (GO) analysis of mRNAs with significantly changed concentrations 
after E. coli K12 exposure (p < 0.05) using DAVID functional annotation analysis (cluster enrichment score >1). 
(d) Logarithm 2 fold change (logFC) and normalized counts (norm. counts) of HMBS, ATP2C1 and LRCH4 
RNAs in platelets exposed to E. coli K12 bacteria compared to control platelets. Cl., Cluster.
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Figure 4. Western blot and ELISA analysis of HMBS and ATP2C1. (a) Cell lysates were applied to SDS-PAGE 
gels under reducing conditions. HMBS and ATP2C1 protein were detected in platelets using a polyclonal 
antibody. Incubation of platelets with E. coli K12 and E. coli O18:K1 in 1:5 or 1:10 platelet-bacteria ratios 
converted HMBS 47 kDa form to a 40 kDa protein. ATP2C1 was not affected. GAPDH was used as a loading 
control. (b) The releasates of the platelet-bacteria mix were collected after centrifugation (500 g, 10 minutes 
without break). HMBS, ATP2C1 and LRCH4 levels were measured by ELISA. Data represents the mean of three 
independent experiments (n = 3). ATP2C1 was detectable in platelet supernatants, while HMBS and LRCH4 
proteins were either not released from platelets or in concentrations below the detection level of the ELISA (data 
not shown). BDL, below detection limit. Western blot results are representative image of three replications. The 
same exposure was applied equally across the entire image. The original pictures of the full-length western blots 
can be found in Supplementary Fig. S7a, b, c, d, g, h.
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ATP2C1 seems to be released from platelets; E. coli exposure seems to reduce the release. It 
is known, that platelets can sequester1,2 and release47,48 RNA and proteins. By ELISA analysis of the supernatant 
obtained after incubation of platelets in buffer for zero and three hours, we observed ~0.5 nanogram/milliliter of 
Figure 5. Effect of platelet activators on HMBS and ATP2C1 proteins. Electrophoretic migration behaviour of 
HMBS and ATP2C1 was analysed in platelets treated with different activators. The molecular weight of HMBS 
in platelets was changed by LPS similar to the changes caused by E. coli K12 and O18:K1. TRAP and ADP had 
no effect on the molecular weights of HMBS and ATP2C1. TRAP, thrombin receptor activating peptide 6; ADP, 
adenosine diphosphate; LPS, lipopolysaccharide. Western blots show representative images of three replicative 
experiments. The same exposure was applied equally across the entire image. The original pictures of the full-
length western blots can be found in Supplementary Fig. S7i, j, k, l, m, n, o, p.
www.nature.com/scientificreports/
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ATP2C1 protein in the supernatant (Fig. 4b). This potential release of ATP2C1 seems to be reduced by the inter-
action of platelets with E. coli K12 and O18:K1, especially when measured at three hours post-incubation. HMBS 
or LRCH4 could not be detected in the supernatant of platelets or platelets exposed to bacteria with the applied 
ELISA assays (data not shown).
Discussion
Platelets are able to interact with different bacteria directly via platelet surface receptors such as P-selectin, glyco-
proteins49 and TLR450, indirectly through plasma proteins51, or via bacteria released exotoxins52. The interaction 
with E. coli can be mediated through FcγRIIa, integrin αIIbβ336 and shiga toxin53 or LPS via TLR454, however the 
latter one seems to be dependent on the surface structure of the bacteria.
We observed that platelet exposure to E. coli K12 led to an increased surface expression of the activation mark-
ers P-selectin and CD63. Presumably, platelets release contents of α- granules and dense bodies upon interaction 
with this bacteria strain. Furthermore, E. coli K12 also triggers PAC-1 antibody and fibrinogen binding to integrin 
αIIbβ3 on platelets in a bacteria concentration dependent manner. The presence of active integrin αIIbβ3 on the 
platelet surface is a prerequisite for platelet aggregation. Interestingly, the pathogenic E. coli O18:K1 was not able 
to induce an increase of the platelet surface activation markers and it also did not significantly affect integrin 
αIIbβ3 activity.
A possible explanation for the difference between the pathogenic and non-pathogenic E. coli may be found in 
the surface of the two strains. E. coli strains carrying an O side-chain on the surface besides the lipid A and core 
oligosaccharides55 are denoted as “smooth”, like the pathogenic E. coli O18:K1. In contrast, “rough” strains lack 
the O-antigen, such as the non-pathogenic E. coli K12. In vitro studies show differences in the activity of the two 
types of LPS, with “rough” LPS activating a broader range of cells with higher efficiency compared to the “smooth” 
form. It has been proven, that macrophages are able to respond to “rough” LPS and lipid A, but not to “smooth” 
LPS56. The “smooth” form requires CD14 to activate immune cells57. Possibly, the same holds true for platelets in 
vitro. Studying the contribution of plasma proteins to platelet - E. coli interaction would be an interesting future 
aspect to consider.
In in vivo comparisons, several studies showed an involvement of the complement system in LPS - induced 
platelet granular release and accumulation. It was found that O-antigen is important, but is not the only viru-
lence factor influencing platelet activation57–59. The fact that in spite of its ability to activate platelets E. coli K12 
is non-pathogenic while O18:K1 cannot activate washed platelets but is pathogenic may be associated with the 
sensitivity to the complement system. While E. coli K12 is a complement sensitive strain, E. coli O18:K1 is com-
plement resistant and uropathogenic. The O antigen on the surface reduces activation of the alternative comple-
ment pathway, and the K1 antigen of this strain inhibits the classical complement pathway60,61. The complement 
resistance may contribute to the survival of the bacteria strain in the blood stream.
We showed that both E. coli strains were able to induce alterations in the platelet RNA repertoire. The E. coli 
K12 exposure lead to a decreased expression of 74 out of 103 RNAs in comparison to platelets not co-incubated 
with E. coli K12.
DAVID GO functional annotation analyses revealed an enrichment of groups of RNAs with common func-
tional characteristics in platelets after incubation with E. coli K12 (cluster enrichment score >1) (Fig. 3c). In 
Cluster 2, Golgi apparatus and membrane related RNAs were enriched. It is known, that in platelets Golgi ele-
ments support selective modification and secretion of molecules, like enzymes or sugar nucleotides62. It has been 
shown that blocking of the Golgi apparatus may result in decreased CD40L expression63. ATP2C1, of which the 
RNA concentration is decreased by the presence of E. coli, is found in this cluster. ATP2C1 has a role in Ca2+/
Mn2+ transport and membrane trafficking, localized on the Golgi apparatus. It has been reported that a deficiency 
of the protein induces defects in secretory pathways64. Interestingly, RNAs annotated to ubiquitination processes, 
GPVI activation and platelet survival were also affected65–67. Platelets with an impaired secretion system cannot 
be activated and cannot release microbicidal components or activate other immune cells. This may result in 
improved survival of bacteria in the blood stream. Cluster 4 comprises 15 RNAs involved in mRNA splicing. 
Perhaps, platelet - E. coli K12 interaction influences splicing and translation of proteins affecting RNA splicing, 
however that needs further investigations. Interestingly, RNAs annotated to cell-cell adhesion (Cluster 5) were 
also enriched. This suggests that cell adhesion mechanisms occurring prior to platelet activation19 may be induced 
by E. coli. A number of other possibly relevant RNAs were also affected.
The analysis of platelet RNA after exposing platelets to bacteria for three hours provides an interesting insight 
into RNA concentration changes. However, including further time points (e.g. 15 minutes, one hour) will reveal 
more information about the expression kinetics of different RNA subsets. Besides, inter-individual variation 
might result in differential platelet reactivity. Kinetic analysis might also add knowledge on the differences expe-
rienced between individuals (Fig. 3d).
It is known that changes in RNA concentrations are not always paralleled by a change of expression of the 
corresponding proteins68. Possibly, a reduced level of a spliced RNA indicates either translation to protein, or 
release of this RNA into the supernatant, or degradation of the RNA. Therefore, we evaluated whether HMBS, 
ATP2C1 and LRCH4 proteins were present and/or affected in platelet lysates and supernatants after exposure to 
E. coli strains.
In humans, two isoforms of HMBS enzyme have been described: a ubiquitously expressed “housekeeping” 
form69 and a shorter erythroid form which is apparently only present in erythropoetic cells70. The role of HMBS 
in platelets remains so far unclear. The two isoforms are transcribed from a single gene, but encoded by two dif-
ferent, alternatively spliced mRNAs. Surprisingly, we did not observe the two alternatively spliced mRNAs, but 
identified two protein forms in platelets. Incubation of platelets with E. coli or with LPS very quickly converts the 
larger into the shorter form. We can only speculate that HMBS may be relevant for platelet-bacteria interaction 
via the LPS pathway.
www.nature.com/scientificreports/
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Interestingly, we found that ATP2C1 was released from platelets incubated without bacteria (~0.5 ng/ml). This 
release happened almost immediately after the start of the incubation, but decreased in platelets co-incubated 
with E. coli K12 and O18:K1. The decrease was more pronounced in the presence of a higher amount of both bac-
teria strains (1:5 and 1:10 platelet to bacteria ratio). The effect of E. coli on the release of ATP2C1 could represent 
a defence mechanism, and it cannot be excluded that similar effects may exist for other platelet-derived proteins. 
The reduced levels of ATP2C1 RNA in the platelets (Fig. 3d) together with the reduced protein levels in the super-
natant could also indicate an active translation of ATP2C1 protein and retention in the platelets in the presence 
of bacteria, even though the qualitative Western blot analysis did not show major differences of this protein in 
platelets incubated without or with E. coli. To clarify what happens to ATP2C1 RNA, protein and its secretion in 
the presence of bacteria will require further studies.
Our results show that the changes of platelet RNA levels induced by bacteria cannot be directly translated 
to the pathogenicity status of bacteria. Non-pathogenic strains which do not trigger sepsis or bacteraemia, can 
still cause changes in platelet RNA and protein profiles, as we could show for E. coli K12; and even though the 
pathogenic E. coli O18:K1 was not able to induce an increase of platelet surface activation markers, it significantly 
affected platelet RNAs and certain proteins. We suspect that the altered RNA and protein expressions could affect 
platelets or other immune cells. Further investigations regarding platelet RNA and protein analysis will be nec-
essary for a more detailed understanding of platelet function in bacterial infections, for instance urinary tract 
infection or sepsis.
Methods
The study was approved by the Ethics Committee of the Medical University of Vienna and all research was per-
formed according to the ethical guidelines.
Isolation of platelets. Citrated blood of healthy donors was used to isolate platelets. The blood was col-
lected at the Department of Transfusion Medicine (Medical University of Vienna), and all donors gave written 
informed consent. Platelet rich plasma (PRP) was prepared using centrifugation at 150 g for 15 minutes at room 
temperature. Since immune-depletion of platelet suspension is not suitable for RNA profiling, PRP was applied 
to an Optiprep (Axis-Shield, Oslo, Norway) density gradient and spun at 350 g for 15 minutes to decrease the 
leukocyte number of the suspension. After harvesting the platelet layer, cells were washed with HEPES-Tyrode 
buffer (10 mM HEPES, 137 mM NaCl, 2.8 mM KCl, 1 mM MgCl2,12 mM NaHCO3, 0.4 mM Na2HPO4, 5.5 mM 
glucose, and 0.35% bovine serum albumin [BSA]). Centrifugation was performed without break, and before 
every centrifugation step, 400 nM prostaglandin I2 (PGI2) (Sigma-Aldrich, Munich, Germany) was added to pre-
vent platelet activation. Washed platelets were resuspended in SSP + buffer (Macopharma SA, Turcoing, France) 
and kept on a see-saw shaker (10 rpm) for one hour before starting the experiments. Platelet and leukocyte counts 
were determined on a Sysmex XE-2100 (Sysmex, Kobe, Japan) instrument.
After optimizing the isolation protocol, the leukocyte contamination (CD45 positivity) of platelet suspensions 
was tested with qPCR. Leukocyte contamination was determined using a standard curve prepared with platelets 
spiked with a different number of leukocytes. Occasional tests of the platelet suspensions showed less than 1 leu-
kocyte/105 platelets, which was considered adequate for RNA sequencing. All samples contained less than 15% 
P-selectin positive platelets after isolation.
Incubation of washed platelets with bacteria. Two different strains of E. coli bacteria were used: 
the non-pathogenic E. coli K12 C600 (purchased from the Coli Genetic Stock Centre; Yale, CT, USA) and the 
uropathogenic E. coli O18:K1 (patient isolate, gift from S. Knapp; Medical University of Vienna). The bacteria 
were grown in lysogeny broth (LB) (Sigma-Aldrich) at 37 °C and 160 rpm until they reached an OD600 nm of 
0.5–0.9. To determine the number of bacteria in the suspensions, OD measurements were performed in sus-
pensions in which the number of colony forming units (CFU)/ml was known. With these data, standard curves 
were prepared. The bacteria cells were pelleted by centrifugation at 18 000 × g for 10 minutes and washed with 
SSP + buffer. After washing, the platelet pellet was resuspended in SSP + and used for in vitro exposure to the 
bacteria in 1:1, 1:5 or 1:10 platelet-bacteria ratio. Incubation was done on a see-saw shaker (10 rpm) at room 
temperature.
In order to monitor the bacteria numbers and physiological status during incubation, platelets, platelets 
co-incubated with E. coli K12 or O18:K1 (in 1:1, 1:5 and 1:10 platelet to bacteria ratio) and bacteria alone as con-
trols (same number of bacteria as mixed with platelets) were plated on LB agar plates after appropriate dilution 
at zero hours and three hours. The agar plates were incubated overnight on 37 °C and the number of colonies was 
counted. The CFU/ml were calculated and the different time points and conditions were compared to each other.
Platelet analysis by flow cytometry. Platelets were identified by expression of CD41 (APC, Clone: HIP8) 
or CD61 (FITC, Clone VI-PL2). To determine possible platelet activation following incubation with bacteria, 
P-selectin (from alpha granules) and CD63 (from dense bodies) expression on the platelet surface was measured 
by flow cytometry. To test integrin αIIbβ3 activation on the platelet surface PAC-1 antibody and antibody-labelled 
fibrinogen were used. At baseline (zero hours) and after three hours incubation the platelet-bacteria mixtures 
(5 × 106 platelets in 1:1, 1:5 or 1:10 platelet to bacteria ratios) were fixed with 0.5% formalin (Roth, Karlsruhe, 
Germany), mixed with antibodies against CD41 (APC, Clone: HIP8), P-selectin (PE, Clone: AK4) and CD63 
(FITC, Clone: H5C6) (BioLegend, San Diego, CA, USA) for 30 minutes and again fixed with 1% formalin. For 
the PAC-1 (FITC, Clone: PAC-1) (BioLegend, San Diego, CA, USA) and fibrinogen (from human plasma, Alexa 
Fluor 647 Conjugate) (Thermo Fisher Scientific, Waltham, MA, USA) assays, the staining procedure was per-
formed without the first fixation step gating for CD61 (FITC, Clone VI-PL2) (BioLegend, San Diego, CA, USA) 
positive platelets during the measurement. All samples were measured after staining using a BD FACSCalibur 
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flow cytometer. Analysis was performed with the FlowJo (TreeStar, Ashland, OR, USA) software, and visualized 
by Graph Pad Prism version 5.01. for Windows (GraphPad Software, La Jolla, CA, USA. www.graphpad.com).
The following platelet activators were used as positive controls: thrombin receptor-activating peptide 6 (TRAP, 
14.5 µM; Roche, Penzberg, Germany), adenosine diphosphate (ADP, 5 µM; Roche) and lipopolysaccharide 
O111:B4 (LPS, 3 µg/ml; Sigma-Aldrich).
RNA isolation. Incubation of washed platelets with bacteria (5 × 108–109 platelets in 1:1 platelet to bacteria 
ratio, for three hours) was followed by centrifugation of the samples at 500 g for 10 minutes. The pellets were used 
for RNA isolation with a standard phenol-chloroform procedure. Briefly, centrifuged cells were resuspended 
in 500 µl Trizol reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA), and added to Phase lock tubes 
(QuantaBio, Beverly, MA, USA) together with chloroform. All centrifugation steps were performed as previously 
described26. The RNA pellet was air-dried and resuspended in 40 µl RNAse free water.
RNA-sequencing library preparation and sequencing. Preparation of RNA samples for sequencing 
was performed as described by Best at al.12. RNA quality and quantity was tested using the RNA 6000 Picochip 
(Bioanalyzer 2100, Agilent, Santa Clara, CA, USA) (Supplementary Fig. S1). For cDNA synthesis and amplifi-
cation ~600 pg total platelet RNA was added to the SMARTer Ultra Low RNA Kit for Illumina Sequencing v3 
(Clontech, Mountain View, CA, USA). The bacteria co-incubated platelet samples contained higher RNA con-
centrations, which reflected bacterial RNA contribution to the total RNA. To make sure that we applied the same 
amount of platelet RNA from samples incubated without or with bacteria, we corrected for the bacteria RNA 
content in our co-incubated samples and added ~1200 pg total RNA to the SMARTer preparation from the bac-
teria exposed samples. The chosen amount of total RNA was based on exemplary sequencing results. Following 
a cDNA quality test on a DNA High Sensitivity chip (Agilent), cDNA samples were sonicated (Covaris Inc., 
Woburn, MA, USA) for nucleic acid shearing. DNA was labelled with the Truseq Nano DNA Sample Prep Kit 
(Illumina, San Diego, CA, USA). The quality check was performed on DNA 7500 chips (Agilent). Then, a 100 bp 
Single-Read sequencing on the Illumina Hiseq. 2500 platform was carried out.
Quantification and statistical analysis of RNA-sequencing data with thromboSeq pipeline. 
The FASTQ-files of the raw RNA-sequencing data were processed using a standardized, platelet optimized 
RNA-sequencing alignment pipeline as previously described11,12. Trimmomatic (version 0.22) was used to clip 
the sequencing adapters and perform 5′-end quality trimming71. Mapping to the human reference genome (hg19) 
was performed with STAR (version 2.3.0, number of mismatches allowed per read: 10)72, and HTseq (version 
0.6.1) was applied to summarize the intron-spanning reads. R (version 3.3.0) and R-studio (version 0.99.902) 
were used to perform normalization, statistical and analytical analyses, particularly using the edgeR package73. 
Gene ontology (GO) analysis was done with Database for Annotation, Visualization and Integrated Discovery 
(DAVID) 6.8 functional cluster annotation74. Platelet specific functional analyses of RNA-sequencing data was 
performed with PlateletWeb database75.
RNA-sequencing analysis with Tuxedo pipeline. RNA-sequencing analysis was also performed with 
the Tuxedo pipeline. For each sample, RNA-sequencing reads passing vendor quality filtering was aligned to the 
hg38 reference genome assembly with the TopHat2 (version 2.1.1)41. Cufflinks (version 2.1.1)43 was used for tran-
scriptome assembly, customary including novel transcript structures, on the basis of the reference transcriptome 
and spliced read alignments, as well as raw transcript quantification. Differential expression was performed with 
Cuffdiff (included in Cufflinks version 2.1.1)42 and R scripts were used to perform quality assessment and further 
refine analysis results. The results were compared to the data produced by thromboSeq pipeline.
Western blot protein analysis. Following incubation (without or with bacteria in 1:1, 1:5 or 1:10 platelet 
to bacteria ratios or activators) platelets were pelleted via centrifugation (at 500 g for 10 minutes, without break) 
and lysed with RIPA buffer containing 2% SDS (Sigma-Aldrich) and 100 µl HaltTM Protease Inhibitor Single-Use 
Cocktail (Thermo Scientific, Boston, MA, USA). The total protein concentration was determined by bicinchonic 
acid protein assay (Thermo Scientific) and we controlled how significantly bacteria cells would influence it. We 
did not observe significant contributions of the bacteria to the measured total protein concentration in samples 
incubated without or with bacteria. Therefore we were confident that we could use an aliquot of 18 µg protein 
for electrophoresis on 8% polyacrylamide gel SDS-PAGE for all platelet samples. Gels were blotted as described 
before26. The blots were incubated overnight with primary anti-human antibodies (rabbit polyclonal ATP2C1 
(1:750), LRCH4 (1:500), HMBS (1:1000) or GAPDH (1:600) from Atlas Antibodies, Bromma, Sweden). Goat 
anti-rabbit (H + L) horseradish peroxidase (HRP) conjugate (1:50000; BioRad, Hercules, CA, USA) served 
as secondary antibody. Signal development was performed by ECL West Pico and West Femto detection sys-
tem (Thermo Scientific); imaging was done with a Bio-Rad Imaging System. The molecular weights of HMBS, 
ATP2C1 and LRCH4 proteins in platelets were compared to the molecular weights of the proteins in HeLa cells 
(Supplementary Fig. S6).
Enzyme-linked immunosorbent assay (ELISA). Platelet releasates were collected from platelets incu-
bated with buffer or bacteria (108 – 5 × 108 platelets in 1:1, 1:5 or 1:10 platelet to bacteria ratios) and used for 
ELISA analyses. Commercially available kits detecting HMBS, ATP2C1 and LRCH4 (DlDevelop, Wuxi, China) 
proteins were applied. Aliquots of 100 µl undiluted supernatants were analysed. The protocols provided by the 
manufacturers were followed.
The datasets generated during the current study are available in the Gene Expression Omibus (GEO) database 
repository (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114710).
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